SCHEMBL2859999

SCHEMBL2859999

COc1ccc(Cn2c(=O)oc(=O)c3cc(OC)c(OC)cc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
RXFP1 Q9HBX9 1/20 0.51
TSHR P16473 4/20 0.49
HTT P42858 4/20 0.49
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 2/20 0.49
P2RX4 Q99571 1/20 0.48
POLB P06746 1/20 0.45
CD74 P04233 2/20 0.45
MIF P14174 2/20 0.45
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
CMA1 P23946 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861684 0.92 SMN1; SMN2 (0.53) KDM4ERXFP1TSHRHTTLMNA
SCHEMBL606151 0.84 IDO1 (0.51) TSHRLMNAALDH1A1P2RX4POLB
SCHEMBL30908758 0.84 IDO1 (0.51) TSHRLMNAALDH1A1P2RX4POLB
SCHEMBL2860677 0.82 P2RX4 (0.68) SMN1; SMN2ALDH1A1P2RX4POLBMIF
SCHEMBL2868888 0.81 MIF (0.46) KDM4ERXFP1TSHRHTTLMNA
SCHEMBL2866988 0.81 MEN1 (0.56) KDM4ETSHRHTTLMNASMN1; SMN2
SCHEMBL3932038 0.80 KDM4E (0.56) KDM4ERXFP1TSHRLMNAP2RX4
SCHEMBL9375422 0.80 POLB (0.57) TSHRP2RX4POLBCD74MIF
SCHEMBL18341934 0.80 P2RX4 (0.48) KDM4ESMN1; SMN2ALDH1A1P2RX4POLB
SCHEMBL2862612 0.79 IDO1 (0.56) SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KDM4E 1057/4885RXFP1 1309/4885TSHR 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.